Intrathecal injection of tigecycline in treatment of extensively drug-resis-tant Acinetobacter baumannii intracranial infection: one case report and literature review
Author:
Affiliation:

Clc Number:

R651.1

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    One patient developed intracranial infection caused by extensively drug-resistant(XDR) Acinetobacter baumannii after intranasal endoscopic optic nerve decompression, intravenous combined intrathecal injection of tigecycline was given, treatment plan was finally determined through comprehensive analysis on relevant literatures in the past five years. Patient received intravenous drip of tigecycline (100 mg initially, followed by 50 mg, q12h) combined with cefoperazone sodium/sulbactam sodium (3.0 g, q8h); intrathecal injection of tigecycline 2.5 mg combined with 5 mL saline, q12h through lumbar cisterna drainage tube, clipping for 2 hours. After intrathecal injection of tigecycline for 15 days, four consecutive routine cerebrospinal fluid examination of patients were all within the normal limits, the culture result was negative, patient was finally cured.

    Reference
    Related
Get Citation

陈宾, 张恒, 赵宗珉,等.替加环素鞘内注射治疗泛耐药鲍曼不动杆菌颅内感染1例报告及文献复习[J].中国感染控制杂志英文版,2019,18(4):335-339. DOI:10.12138/j. issn.1671-9638.20194262.
CHEN Bin, ZHANG Heng, ZHAO Zong-min, et al. Intrathecal injection of tigecycline in treatment of extensively drug-resis-tant Acinetobacter baumannii intracranial infection: one case report and literature review[J]. Chin J Infect Control, 2019,18(4):335-339. DOI:10.12138/j. issn.1671-9638.20194262.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:September 18,2018
  • Revised:
  • Adopted:
  • Online: April 28,2019
  • Published: